Linaclotide Compares with Macrogol 4000 Powder in Treatment of Functional Constipation: A Prospective Cohort Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300069934

Enrollment

Unknown

Registered

2023-03-29

Start date

2021-06-01

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

functional constipation

Interventions

Treatment group:linaclotide

Control group:macrogol 4000 powder

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) age = 18 years and = 70 years; (2) male or female; (3) voluntarily accept and comply with this experimental protocol, and accept the review and follow-up on time; (4) sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) pregnant and lactating women, or female patients with childbirth plans during the study period; (2) patients with concomitant psychiatric disorders; (3) patients with allergies or contraindications to the drugs used in this study; (4) patients who have used other gastrointestinal drugs within the previous 2 weeks; (5) patients with gastrointestinal tumors, history of gastrointestinal surgery, inflammatory bowel disease, intestinal obstruction, or gastrointestinal bleeding; (6) cases with poor overall judgment of compliance.

Design outcomes

Primary

Measure	Time frame
complete spontaneous bowel movement;	—

Secondary

Measure	Time frame
Bristol stool form scale;Cleveland Constipation Score;	—

Countries

China

Contacts

Public ContactZhan Yu

Chengdu Integrated TCM & Western Medicine Hospital

277546066@qq.com18628266002

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026